The complement system, neuronal injury, and cognitive function in horizontally-acquired HIV-infected youth by Jennifer L. McGuire et al.
The complement system, neuronal injury, and cognitive function
in horizontally-acquired HIV-infected youth
Jennifer L. McGuire1,2,3 & Alexander J. Gill2 & Steven D. Douglas3,4,5 &
Dennis L. Kolson2 & CNS HIVAntiretroviral Therapy Effects Research (CHARTER)
Group
Received: 7 December 2015 /Revised: 13 May 2016 /Accepted: 26 May 2016 /Published online: 6 June 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract The complement system (C1q/C3) is a key me-
diator of synaptic pruning during normal development.
HIV inappropriately induces C1q and C3 production in
the brain, and reduces neuronal complement inhibition.
HIV may thus alter neural connectivity in the developing
brain by excessively targeting synapses for elimination.
The resultant pattern of neuronal injury may fundamen-
tally alter neurodevelopmental and cognitive processes
differentially across ages. This study aimed to (1) mea-
sure the association between the cerebrospinal fluid
(CSF) complement factors (C1q/C3) and a marker of
neuronal injury (NFL) in HIV+ subjects; (2) quantify
the differences in CSF C1q/C3 between HIV+ youth
and older adults; and (3) define the relationship between
CSF C1q/C3 and cognitive impairment in each age
group. We performed a retrospective cross-sectional
study of 20 HIV+ 18–24-year-old youth and 20 HIV+
40–46-year-old adults with varying levels of cognitive
impairment enrolled in the CNS Antiretroviral Therapy
Effects Research study. We quantified C3, C1q, and NFL
by ELISA in paired CSF/plasma specimens. We found
that CSF C1q correlates with NFL in all subjects not
receiving antiretroviral therapy (n = 16, rho = 0.53,
p = 0.035) when extreme NFL outliers were eliminated
(n = 1). There was no difference in plasma/CSF C1q or
C3 between older adults and youth. In 18–24-year-old
youth, a nearly significant (p = 0.052) elevation of CSF
C1q expression was observed in cognitively impaired
subjects compared to cognitively normal subjects.
Further investigation into the role of the CNS comple-
ment system in the neuropathogenesis of HIV is warrant-
ed and should be considered in a developmentally spe-
cific context.
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Introduction
The complement system is a key mediator of synaptic
pruning during normal development (Stevens et al. 2007;
Stephan et al. 2012), and when inappropriately activated
later in life, has been implicated as one mechanism of syn-
apse elimination in a variety of different neurodegenerative
diseases (Alexander et al. 2008; Stephan et al. 2012).
Complement factors are locally synthesized in the brain
and are developmentally regulated in localized patterns.
C1q and C3 appear to be particularly important in tagging
weak or unnecessary synapses for removal via microglia
complement receptor-mediated phagocytosis. Consistent
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with this function, C1q- and C3-deficient mouse models
have large and persisting defects in central nervous system
(CNS) synaptic connectivity (Stevens et al. 2007).
Furthermore, C3 and CR3 knockout mice have more struc-
tural synapses in the visual system than wild-type counter-
parts, suggesting that altered complement signaling early
in development results in sustained defects in synaptic con-
nectivity (Schafer et al. 2012).
The role of the complement system in HIV has been exten-
sively studied in the periphery. Complement is activated early
in HIV infection via a variety of mechanisms, but it fails to
eradicate HIV from infected cells and from the circulation due
to the presence of complement regulators within the HIV-1
envelope and on infected cells (Liu et al. 2014). Instead,
HIV uses complement activation to spread and enhance sys-
temic infection (Liu et al. 2014). The role of complement in
the neuropathogenesis of HIV is less well understood. Local
HIV infection induces C3 production in neuronal and glial cell
lines incubated with HIV and in parallel downregulates nor-
mal complement inhibitor proteins (CD59) (Stephan et al.
2012; Liu et al. 2014). In a simian immunodeficiency virus
(SIV) model, cerebral synthesis of C1q and C3 was upregu-
lated compared to controls and deposited on neuronal mem-
branes (Speth et al. 2004). In human cerebrospinal fluid
(CSF), C3 levels are elevated in HIV+ subjects with signs of
CNS dysfunction compared to uninfected controls, as are C3
CSF:serum ratios in HIV+ subjects compared to uninfected
controls (Jongen et al. 2000). In human neuropathologic stud-
ies, complement component upregulation was demonstrated
in the neostriatum of individuals with HIV-encephalitis
(Gelman et al. 2012), the traditional pathological correlate of
HIV-associated dementia (HAD).
These HIV-specific observations of the complement sys-
tem in the context of our emerging understanding of its role
in normal developmental synaptic pruning raise several perti-
nent questions in the study of neuroHIV across the age span.
First, does complement alter neural connectivity in HIV by
excessively targeting synapses for elimination? And second,
does any resultant pattern of neuronal injury fundamentally
alter neurodevelopmental and cognitive processes differential-
ly across ages depending on normal pre-existing complement
developmental regulation? Approximately one quarter of the
50,000 new HIV infections in the USA per year are among
13–24-year-old youth (Centers for Disease Control and
Prevention 2015). Normal neural circuit maturation continues
from infancy into young adulthood (up to 30 years of age),
requiring activity-dependent pruning of inappropriate synap-
tic connections in order to reinforce and strengthen appropri-
ate connections (Giedd et al. 1999). It is therefore important to
study and understand the age-specific effects of acquired HIV
on the actively developing brain in order to tailor future
ontogenetic-appropriate interventions and prevention strate-
gies in neuroAIDS.
No published studies to date have examined the relation-
ships between the CNS complement system and markers of
neuronal injury in HIV infection. Neurofilament light chain
(NFL) is a structural protein specific to neurons that is released
into the CSF and blood following axonal disruption (Julien
1999; Pasol et al. 2010; Gresle et al. 2011). In HIV infection,
CSF NFL levels appear to be an appropriate surrogate marker
for neuronal damage. CSF NFL is elevated in early and later
infection in subjects with and without cognitive impairment
(Peluso et al. 2013; Jessen Krut et al. 2014), although levels
are highest in HIV-associated dementia (HAD) (Gisslen et al.
2007; Abdulle et al. 2007; Mellgren et al. 2007) and fluctuate
in response to combined antiretroviral therapy (increase with
interruption and decrease with initiation) (Abdulle et al.
2007).
In order to begin to examine the role of the CNS comple-
ment sys tem as one mechanis t ic p layer in HIV
neuropathogenesis, we sought to elucidate the relationship
between complement factors and neuronal damage in HIV
infection across the developmental age span. Specifically,
we measured the correlations among CSF and plasma com-
plement factors (C1q and C3) and NFL as a marker of neuro-
nal injury. We then examined the differences in complement
protein concentrations in youth and older adults, and finally
explored the relationship between these markers and cognitive
function in each age group.
Methods
Study design and setting
We performed a retrospective cross-sectional study using
biological samples (plasma, CSF) and data from 40
HIV+ subjects enrolled in the CNS HIV Antiretroviral
Therapy Effects Research (CHARTER) cohort of the
NIMH/NINDS/NIH. Characteristics of the CHARTER
cohort are described elsewhere (Heaton et al. 2010).
Briefly, CHARTER is an ongoing, observational cohort
study that enrolled 1561 HIV-infected persons between
2003–2007 from six US university-affiliated HIV treat-
ment centers. Inclusion criteria for the CHARTER study
were broad, but individuals with severe comorbid psychi-
atric, medical, or neurological disorders deemed likely to
adversely affect cognitive functioning were excluded.
HIV-negative subjects were not included in CHARTER.
Our study used data and samples from 40 CHARTER
subjects (20 each 18–24 years old and 40–46 years
old). The cohort included men and women of any
race/ethnicity with a spectrum of cognitive dysfunction,
on and off antiretroviral therapy (ART), and who
underwent successful lumbar puncture, venipuncture,
and neuropsychological testing. Subjects with known
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hepatitis C infection, a concurrent diagnosis of syphilis,
active substance abuse, a history of CNS opportunistic
infection, head trauma, epilepsy, multiple sclerosis, other
known causes of autoimmune dysfunction, mental retar-
dation or dementia, psychotic disorder, or other chronic
illness were excluded.
Data collection
Original data collection for the CHARTER cohort was
approved by the Human Subjects Protection Committees
of each participating institution. All subjects provided
written consent to participate in the CHARTER study.
Data were originally obtained through comprehensive
neuromedical, neurocognitive, psychiatric, and functional
evaluations, and collection of blood, urine, and CSF sam-
ples (Heaton et al. 2010). The de-identified data and bio-
logical samples for the present substudy were obtained
with permission of the CHARTER steering committee.
Because the dataset and samples were de-identified and
because our substudy did not involve patient contact, The
Children’s Hospital of Philadelphia institutional review
board determined (June 22, 2015) that this study did not
qualify as human subjects research.
Laboratory assessments
HIV infection was diagnosed by ELISA with Western
blot confirmation. Clinical laboratory assessments, in-
cluding complete blood counts, chemistry panels, and
flow cytometry for CD4+ T lymphocyte count were per-
formed at each CHARTER site’s Clinical Laboratory
Improvement Amendments (CLIA) certified, or CLIA
equivalent, medical center laboratory. Plasma HIV
RNA measurements (viral loads) were quantified by a
RT-PCR ultrasensitive assay (nominal lower quantitation
limit 50 copies per mL; Amplicor®, Roche Diagnostic
Systems, Indianapolis, IN) in a central lab (Heaton et al.
2010).
Biomarkers for the present substudy were measured in trip-
licate by validated, commercially available 96-well plate
ELISAs on stored, frozen samples (−80C). Paired CSF/
plasma samples were assayed for C3 (Abcam, limit of detec-
tion 0.2 μg/mL [plasma, catalog number ab108822], 0.5 ng/
mL [CSF, catalog number ab108823]) and C1q (Abcam cata-
log number ab170246, limit of detection 0.03 ng/mL). CSF
samples were assayed for NFL (Uman Diagnostics AB, limit
of detection 31 ng/mL). Previous work by our group did not
demonstrate measurable quantities of NFL in plasma
(McGuire et al. 2015) so this was not assayed in the present
study.
Neurocognitive assessments
All CHARTER study subjects completed a comprehensive
neuropsychological test battery assessing verbal fluency, ex-
ecutive functioning, speed of information processing, learn-
ing, recall, working memory, and motor skills. Raw test scores
were converted to demographically adjusted T scores using
the best available normative data accounting for age, sex, eth-
nicity, and education. Functional impairment was assessed
using the Patient’s Assessment of Own Functioning
Inventory (PAOFI) and an instrumental activities of daily liv-
ing (IADL) questionnaire (Heaton et al. 2010). A global per-
formance score was determined as previously described
(Carey et al. 2004; Woods et al. 2004). HIV-associated
neurocognitive disorder (HAND) status was classified accord-
ing to Frascati criteria (Antinori et al. 2007).
Data analysis and statistical methods
Data were analyzed using Stata version 14.0 (StataCorp,
College Station, Texas, 2015). Non-parametric analysis
methods were used given small sample sizes to improve ac-
curacy of statistical estimates and reduce sensitivity of analy-
ses to any statistical outliers. Continuous variables were de-
scribed using median and intraquartile range (IQR), and inter-
group differences were evaluated using the Wilcoxan rank-
sum tests and Kruskal-Wallis tests. Categorical variables were
described using counts and percents, and intergroup differ-
ences were compared using the Chi-square test. Spearman’s
correlation coefficients were used for correlations between
biomarkers. Statistical significance was determined a priori
as a two-tailed p value <0.05.
Results
Cohort demographics, clinical, and laboratory characteristics
of everyone and of each specific age group are summarized in
Table 1. Among the 40 total subjects examined, 88 % were
male and 33 % were African American. As expected, older
adults had a longer duration of infection (median 8.3 years
versus 1.2 years, p = 0.005), and a subsequent lower nadir
CD4+ T lymphocyte count (median 109 versus 298 cells/
mm3, p = 0.020). Other markers of systemic infection (HIV-
1 RNA viral load, current CD4+ T lymphocyte count) were
similar between the different age groups. Older adults trended
towards more frequent current ART use (70 % versus 45 %,
p = 0.053), likely related to duration of time linked into ap-
propriate care and counseling. Younger adults had higher
Wide Range Achievement Test (WRAT) scores (102 versus
90, p = 0.025), suggesting a higher level of premorbid cogni-
tive functioning despite comparable total years of education. It
is unclear if this difference is simply reflective of the
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population currently being infected with HIV, or if it is age-
related. However, all neurocognitive data are adjusted for age
and demographic factors, making the latter possibility less
likely. HAND diagnoses were comparable between the two
age groups. Finally, no subjects were using illicit drugs at the
time of this study.
To examine the association between CSF complement pro-
teins and neuronal injury in HIV, we first measured CSF ex-
pression of C1q/C3 and NFL. Analyses were conducted 1)
with the entire cohort, and 2) restricted to subjects not receiv-
ing ART in order to avoid any potential confounding effects of
ART on expression of biomarkers of neuroimmune dysregu-
lation or neuronal injury. There were no significant correla-
tions between NFL and either CSF complement marker in the
overall cohort. However, the correlation between CSF C1q
and NFL in subjects off ART (n = 17) did approach statistical
significance (rho = 0.338, p = 0.184). We subsequently per-
formed an exploratory analysis eliminating outlier NFL values
(defined by value ≥3SD above median) that demonstrated a
significant relationship between CSF C1q and NFL (n = 16,
rho = 0.53, p = 0.035) (Fig. 1a). These findings suggest that
complement may be linked to neuronal injury. Whether this is
a parallel finding in the neuropathogenesis of HIVor causal is
unclear in this cross-sectional analysis. Furthermore, both
CSF C1q and C3 correlate closely with each other
(rho = 0.5, p = 0.001) (Fig. 1b), suggesting these data are
likely demonstrating true differences in activation of the com-
plement system.
To determine whether the proposed relationship between
CSF C1q and NFL may be clinically significant, we next
compared expression of CSF complement factors with the
presence or absence of cognitive impairment (defined as meet-
ing Frascati criteria for asymptomatic neurocognitive impair-
ment [ANI], mild neurocognitive disorder [MND], or HIV-
associated dementia [HAD]). Of note, four of the 40 total
subjects were not classified for HAND so were therefore ex-
cluded from this analysis. In 18–24 year-old youth, a nearly
significant (p = 0.052) elevation of CSF C1q expression was
observed in cognitively impaired subjects compared with cog-
nitively normal subjects (median 2.13 versus 0.86ug/mL,
p = 0.052) (Fig. 2). This difference was not observed across
the entire cohort, and there was no difference in C3 in any age
group by cognitive impairment. Finally, there were no signif-
icant differences in either CSF complement protein concentra-
tion across specific cognitive subdomains of impairment, as
measured by domain-specific deficit scores (data not shown).
Table 1 Demographic, HIV, and cognitive characteristics of the study population
Characteristicsa All n = 40 Youth (18–24 yearsold)
n = 20




Male sex 35 (88) 18 (90) 17 (85) 0.633
Black race 13 (33) 6 (30) 7 (35) 0.986
Age (years) 32 (22–42) 22 (20.5–23.5) 42 (40–43.5) <0.001
HIV variables
Duration of HIV (years) 3.1 (0.5–11.2) 1.2 (0.3–3.1) 8.3 (3.3–14.1) 0.005
Currently using ART 23 (58) 9 (45) 14 (70) 0.053
CD4 nadir 233 (59–410) 298 (199–521) 109 (35–356) 0.020
Plasma CD4+ count: 50–199 6 (15) 2 (10) 4 (20) 0.587
200–349 10 (25) 6 (30) 4 (20) –
≥ 350 24 (60) 12 (60) 12 (60) –
Plasma HIV-1 RNA (log) 2.96 (1.70–3.90) 2.96 (1.60–4.23) 2.96 (1.70–3.55) 0.815
CSF HIV-1 RNA (log) 1.70 (1.70–2.36) 1.70 (1.60–2.71) 1.70 (1.70–2.24) 0.750
Cognitive variables
Education (years) 12 (11–13) 12 (11.5–13) 13 (10.5–14.5) 0.335
WRAT score 93.5 (83–108) 102 (90–112) 90 (76–100) 0.025
HAND normal 17 (43) 7 (35) 10 (50) 0.548
ANI, n(%) 17 (43) 10 (50) 7 (35) –
MND, n(%) 1 (3) 0 (0) 1 (5) –
HAD, n(%) 1 (3) 1 (5) 0 –
Not classified 4 (10) 2 (10) 2 (10) –
a Categorical variables are described using n(%). Continuous variables are described using median (IQR)
b p values to compare characteristics between age groups were calculated using chi-square tests for categorical variables and the Wilcoxan rank-sum
(Mann-Whitney U) tests for continuous variables
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There were no differences in C1q or C3 expression (in
plasma or CSF) between older adults and youth, on or off
ART (data not shown). NFL was significantly lower in youth
compared to older adults across the cohort (median 341 versus
677 pg/mL, p = 0.001) (Fig. 3), consistent with prior reports in
the literature that NFL is generally higher with advancing age
(Jessen Krut et al. 2014). Furthermore, CSF NFL expression
was inversely correlated with CD4+ T lymphocyte nadir
(rho = −0.39, p = 0.013; data not shown), demonstrating a
consistent relationship between systemic immune status and
risk of CNS neuronal injury previously demonstrated in stud-
ies of older-aged HIV cohorts (Abdulle et al. 2007). Finally,
CSF expression of C1q and C3 did not correlate with plasma
expression C1q or C3, or clinical markers of systemic HIV
disease progression, including CD4+T lymphocyte nadir, cur-
rent systemic CD4+ T lymphocyte count, or plasma/CSF viral
load. These observations support the concept that CSF com-
plement proteins are likely locally produced and regulated and
not directly linked to peripheral immune dysregulation.
Measuring complement levels in plasma moving forward is
therefore likely not a good surrogate for CSF levels in clinical
studies.
Discussion
This is the first study to examine CSF complement protein
expression as a novel immunologic mediator of HIV-
associated neuronal damage in human subjects. It is also the
first study to address the possibility of an age-specific ontoge-
netic neuropathogenesis of acquired HIV infection. We have
demonstrated a potential positive correlation in this small co-
hort between CSF expression of C1q and NFL in subjects of
all ages not receiving ART. These data suggest that C1q in
CSF may be a correlate or biomarker for neuronal injury
across the age span in HIV. Furthermore, in 18–24-year-old
youth we found a nearly significant elevation of CSF C1q
expression in cognitively impaired subjects to cognitively nor-
mal subjects. This second observation may reflect an age-
specific vulnerability to complement-mediated cognitive dys-
function. Finally, we have confirmed a positive correlation
between CSF expression of C1q and C3, suggesting our data
are likely demonstrating true differences in activation of the
complement system, rather than anomalous assay results.
Borderline statistical significance may thus reflect actual bio-
logical significance but too small of a sample size for defini-
tive results.
C1q is a 460 kDa hexameric glycoprotein that serves as a
pattern recognition molecule and the first recognition
Fig. 1 a There is a positive correlation between CSF C1q and NFL in
subjects of all ages not currently receiving antiretroviral therapy (one
outlier >3 SD removed). b There is a positive correlation between C1q
and C3 in CSF. Correlations were analyzed using Spearman’s correlation
coefficients
Fig. 2 In 18–24 year-old youth, C1q was higher in cognitively impaired
subjects compared to neurocognitively normal (NCN) subjects (median
2.13 versus 0.86ug/mL, p = 0.052)
Fig. 3 NFL was significantly lower in youth compared to older adults
across the cohort (median 341 versus 677 pg/mL, p = 0.001)
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subcomponent of the complement classical pathway. It binds
HIV, IgG, IgM, and many other ligands and receptors largely
via a gC1q domain (Kouser et al. 2015). It is locally produced
in the CNS, likely by microglia, astrocytes, and neurons, and
is generally upregulated during stress, injury, or infection. In
addition to its roles in infection control, C1q plays a vital role
with the complement cascade in normal synapse elimination
during brain development (Stevens et al. 2007). Furthermore,
in older adults, C1q has been associated with microglial acti-
vation and enhanced microglial-mediated phagocytosis,
astrogliosis, and protection of neurons from β-amyloid and
serum amyloid P-induced neurotoxicity (Kouser et al. 2015).
It therefore balances function between neuroinflammation and
neuroprotection depending on the context within which it is
activated.
In the present study, we present preliminary evidence that
C1q may be related to neurodegeneration. Whether that is via
microglial activation and subsequent inflammatory
excitotoxicity, or whether this relationship is simply a non-
causal association is not yet clear. The fact that higher levels
of C1q may be associated with cognitive impairment in youth
suggest that C1q is likely at least a part of the causal pathway
between HIV infection and neuronal damage, assuming neu-
ronal damage is underlying cognitive dysfunction in HIV.
This specificity of this finding in youth may reflect a biolog-
ical relevance of normal complement developmental regula-
tion in HIV neuropathogenesis. Specifically, synapses may be
more vulnerable to a complement-mediated mechanism of
neuronal destruction at certain developmental stages, perhaps
due to a lack of local complement inhibition physiologically
meant to permit normal developmental pruning processes.
Notably, while our sample size was low, C1q was not as-
sociated with systemic markers of HIV progression such as
plasma HIV-1 RNA level (viral load) and CD4+ T lympho-
cyte count. This observation supports the idea that at least part
of HIV neuropathophysiology occurs independently of pe-
ripheral disease and is clinically consistent with the fact that
mild forms of HAND persist in the antiretroviral era in sub-
jects with good systemic viral control.
There have been several recent compelling studies exam-
ining the presence of systemic inflammatory markers in youth
with different developmental synaptopathies, including peri-
natally acquired HIV. One such study demonstrated an inverse
correlation between serum markers of three combined pro-
inflammatory markers (IL-6, C-reactive protein [CRP], fibrin-
ogen) and processing speed, suggesting that residual inflam-
mation may contribute to neurocognitive deficits despite well-
controlled HIV disease in the periphery (Kapetanovic et al.
2014). While adolescents with behaviorally acquired HIV in-
fection are a very different population in phenotype and viral
pathogenesis than children with perinatal infection, these find-
ings do raise interesting questions about the role of general
systemic inflammation in HIV neuropathogenesis and how
this may affect the CNS complement system. Biochemically,
CRP can bind C1q and activate the classical complement cas-
cade in the periphery. However, in the CNS, it is the mannose-
binding lectin (MBL) pathway that is active, tagging synapses
for microglial phagocytosis (Stevens et al. 2007). Thus, it is
probably unlikely that CRP or other systemic pro-
inflammatory cytokines are driving complement-mediated
pathogenesis in the CNS. Instead, it is possible that inflamma-
tory mediators in the periphery may help drive activated and
infected monocytes into the CNS and thus perpetuate HIV
neuropathogenesis (Fischer-Smith et al. 2008). Other inflam-
matory mediators known to be upregulated in the CSF of
HIV+ individuals (e.g., monocyte chemoattractant protein
(MCP)-1, beta-2-microglobulin, Substance P, IL-6, etc.) do
not have an obvious direct link to complement activation.
Our study had several limitations. First, because wewanted
to specifically include a comparable number of 18–22-year-
old youth compared to older adults, the overall cohort size was
relatively small (n = 40 total), because there are fewer speci-
mens available from younger adults in the CHARTER cohort.
Thus, overall analyses and sub-analyses with even smaller
numbers (e.g., the relationship between C1q and NFL in sub-
jects off ART) may be underpowered, and truly significant
associations may therefore be underestimated. Second, while
19/36 subjects did have cognitive impairment (four were not
classified), most of these (17/19) were mild (ANI). Therefore,
linear correlations of complement markers with degree of im-
pairment are limited. This is why we chose to use cognitive
impairment as a binary variable in the majority of our analy-
ses. Third, because of these small numbers and the cross-
sectional nature of this correlation study, factors confounding
the relationship between complement proteins and NFL are
not accounted for in statistical associations. However, univar-
iate analysis did not suggest relationships between comple-
ment proteins and systemic markers of disease, or peripheral
complement levels, so not including these variables in subse-
quent models likely had little effect on the associations exam-
ined. In addition, causality cannot be inferred in a cross-
sectional study. Finally, in our statistical analysis, we had sev-
eral outlier values for NFL that we were not able to biologi-
cally explain why they otherwise differed from the remainder
of the cohort. While the non-parametric analyses we usedwith
our data should minimize the impact of outliers on statistical
associations, a larger cohort would allow us in the future to
determine if these subjects have a different specific biological
reason for elevations in NFL, or if they were indeed spurious.
We chose to investigate the role of the complement system
in HIV neuropathogenesis based on several recent articles by
Stevens et al. (2007) and Stephan et al. (2012) reviewing the
role of complement proteins in synaptic elimination and prun-
ing. While HIV does not infect neurons, cognitive impairment
in HIV is associated with pathological evidence of synaptic
loss and dendritic simplification, as well as infection and
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activation of CNS infiltrating monocyte-derived macrophages
and microglia (Masliah et al. 1997; Cherner et al. 2002; Ellis
et al. 2007). Given the known interplay between the very
complex complement system and HIV in the periphery, the
question of the role of complement in HIV infection in the
CNS is quite compelling. In summary, to date, we have dem-
onstrated a tentative correlation between CSF expression of
C1q and NFL in subjects not receiving ARTacross all ages, as
well as a higher C1q expression associated with impaired
neurocognitive function in 18–24 year old youth. These find-
ings support the possibility of the complement system as a
novel mediator of HIV neuropathogenesis and beg the ques-
tion of whether a specific ontogenetic mechanism exists be-
hind this neuropathogenesis. Future larger CSF studies and
subsequent neuropathological studies are necessary to deter-
mine if these relationships are maintained in larger cohorts and
tissue specimens. If so, these finding may have future thera-
peutic implications for novel mechanisms of adjunctive, age-
specific HAND therapies (e.g. complement inhibitors).
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